Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.50
Bid: 18.00
Ask: 19.00
Change: 0.00 (0.00%)
Spread: 1.00 (5.556%)
Open: 18.50
High: 19.00
Low: 18.50
Prev. Close: 18.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Geomerics Update

26 Mar 2012 07:00

RNS Number : 9988Z
Angle PLC
26 March 2012
 



For immediate release

26 March 2012

 

ANGLE plc

 

("ANGLE" or the "Company")

 

GEOMERICS EXPANDS PRODUCT RANGE AND SALES

 

 

ANGLE plc (AIM: AGL), the technology commercialisation company, is pleased to announce positive progress in new products, sales and market recognition at its 33%-owned portfolio company Geomerics, which specialises in computer games middleware.

 

At the recent Game Developers Conference (GDC 2012) in San Francisco, Geomerics announced the development of new products for mobile devices and for Nintendo's new Wii™ U console. These new products significantly expand the addressable market for Geomerics products.

 

The company demonstrated a range of new technologies aimed at rounding out the Enlighten offering and getting 'next gen ready'. In partnership with ARM, they showcased Enlighten running smoothly on a Mali-based Samsung Galaxy Tab 7.7 tablet on the expo floor. This is an expansion of Geomerics' product capability and Enlighten, via ARM CPU, now supports a wide range of mobile devices including the iOS-based iPad and iPhone, Android devices and PlayStation® Vita, offering new sales opportunities.

 

Geomerics also announced its new product capability for Nintendo's new Wii™ U console, the successor to the highly successful Wii™ adding to its capability on the PC, PS3 and Xbox360. Geomerics also displayed on the NVIDIA and Intel booths at GDC 2012, reaffirming their commitment to high-end gaming experiences on the PC and console.

 

Geomerics sales continue to strengthen. Since GDC 2012 finished on 9th March, Geomerics has already been notified of four new sales for major new games, three of which are to entirely new customers, and its pipeline of prospective customers is steadily increasing.

 

Finally, there has been further market recognition for Geomerics' Enlighten with a BAFTA award being won by a computer game incorporating the Enlighten lighting solution.

 

The British Academy of Film and Television Arts (BAFTA) 2011 GAME Award has been awarded to Battlefield 3, an Electronic Arts game incorporating Enlighten. The GAME Award recognises the best game of the year, and is the only category at the British Academy Video Games Awards to be voted for by the general public.

 

Battlefield 3 is the fastest selling Electronic Arts game ever, selling more than 5 million units in its first week of release. Enlighten is the only real-time global illumination solution available for computer games, enabling the lighting to be realistically calculated in real-time as the player interacts with the game environment and other players. As a result, Enlighten provides a much more realistic player experience.

 

The reviews of Battlefield 3 have frequently singled out the lighting. For example The Guardian reported "Visually Battlefield 3 is a marvel of beautiful lighting effects" and GameSpy in its review said "Once they see the light - they'll understand what a special game Battlefield 3 is". The quality of the lighting and graphics in general has been a major contributor to the success of the game.

 

In a first time win at the BAFTA awards for the Battlefield franchise, it beat titles including FIFA 12, The Elder Scrolls V: Skyrim and Batman: Arkham City. Also, for the first time Battlefield beat the long-standing favourite Call of Duty, which has dominated the GAME Award for the past three years.

 

 

Gary Lewis, Chief Executive of Geomerics, commented:

"The BAFTA award for Battlefield 3 is an excellent further endorsement of the success of the game. We are pleased with ongoing adoption of the Enlighten technology in major new games. 2012 looks like being a great year for us and the expansion into mobile computing offers substantial growth potential for the future."

 

 

Andrew Newland, Chief Executive of ANGLE commented:

"We are delighted by Geomerics' ongoing success and believe the company is positioned well for the future."

 

 

 

 

 

For further information:

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Cenkos Securities

Stephen Keys, Adrian Hargrave (Nominated adviser)

Andy Roberts (Sales)

 

020 7397 8900

Buchanan

Mark Court, Sophie Cowles

 

020 7466 5000

Scott Harris

Stephen Scott, Harry Dee

0207 653 0030

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCQXLFLLXFFBBL
Date   Source Headline
24th Feb 20147:00 amRNSUse of Parsortix System with Liver Cancer Patients
18th Feb 20147:00 amRNSParsortix Launch at Circulate Conference in Berlin
30th Jan 20147:00 amRNSInterim Results
13th Jan 20147:00 amRNSCambridge Parsortix Laboratory
10th Jan 20147:00 amRNSNotification of Interim Results and Webcast
7th Jan 20147:00 amRNSAppointment of Scientific Adviser
17th Dec 20137:00 amRNSCE Mark Authorisation
13th Dec 20137:00 amRNSRaises £6.2m from Sale of Geomerics
31st Oct 20133:31 pmRNSResult of 2013 Annual General Meeting
9th Oct 20137:00 amRNSAnnual Report and Accounts and Notice of AGM
31st Jul 20137:00 amRNSPreliminary Results
25th Jul 20137:00 amRNSPositive Evaluation of Parsortix System
19th Jul 20137:00 amRNSNotification of Preliminary Results and Webcast
8th Jul 20137:00 amRNSParsortix Colorectal Cancer Validation
29th May 20137:00 amRNSDirector's Share Transfer
28th May 20137:00 amRNSParsortix Manufacturer Appointed
13th May 20137:00 amRNSPARSORTIX CELL HARVESTING
7th May 20137:00 amRNSParsortix Regulatory Approval Update
28th Feb 20137:00 amRNSParsortix Research Product Launch
15th Feb 201310:56 amRNSDirector's share transfer
31st Jan 20137:01 amRNSFundraising and Director's Dealings
31st Jan 20137:00 amRNSInterim Results
16th Jan 20137:00 amRNSNotification of Interim Results and Webcast
14th Jan 20137:00 amRNSParsortix Cell Recovery
7th Jan 20137:00 amRNSAppointment of NED
18th Dec 20127:00 amRNSParsortix Released to Research Partners
10th Dec 20127:00 amRNSBUSINESS UPDATE
18th Oct 20127:00 amRNSAppointment of Scientific Advisers
17th Oct 20123:45 pmRNSHolding(s) in the Company
11th Oct 20123:39 pmRNSResult of 2012 Annual General Meeting
3rd Sep 20127:00 amRNSIncreased Fundraising
1st Aug 20127:00 amRNSIncreased Fundraising
26th Jul 20127:01 amRNSFundraising
26th Jul 20127:00 amRNSPreliminary Results
24th Jul 20127:00 amRNSNotice of Preliminary Results and Conference Call
27th Jun 20127:00 amRNSOffer Unconditional for Novocellus' Partner Origio
7th Jun 20127:00 amRNSUpdate Re Novocellus' Partner ORIGIO A/S
16th May 20127:00 amRNSGeomerics Milestone Payment
30th Apr 20127:00 amRNSParsortix Design Breakthrough
26th Apr 20127:00 amRNSLaunches New Corporate Website
23rd Apr 20127:00 amRNSParsortix Update for Breast Cancer
17th Apr 20127:00 amRNSParsortix Validation for Ovarian Cancer
11th Apr 20127:00 amRNSNovocellus Embryosure® Trial Started
26th Mar 20127:00 amRNSGeomerics Update
15th Mar 20127:00 amRNSParsortix Validation for Colon Cancer
7th Mar 20128:00 amRNSHolding(s) in the Company
28th Feb 201212:00 pmRNSDirector Share Transfer
28th Feb 20128:00 amRNSTotal Voting Rights
27th Feb 20127:00 amRNSParsortix Research Partnership
22nd Feb 20127:00 amRNSSecond Novocellus Patent

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.